Champions Oncology Inc (NASDAQ:CSBR) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price objective of $14.33 for the company and are forecasting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Champions Oncology an industry rank of 84 out of 257 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 price objective for the company in a research note on Monday, September 17th.

Shares of Champions Oncology stock traded down $0.40 on Wednesday, hitting $9.95. The stock had a trading volume of 10,242 shares, compared to its average volume of 122,783. Champions Oncology has a twelve month low of $3.05 and a twelve month high of $17.90. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.73 and a quick ratio of 0.73. The company has a market capitalization of $113.77 million, a P/E ratio of -70.57 and a beta of 0.57.

Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings data on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.03. Champions Oncology had a negative return on equity of 97.02% and a negative net margin of 1.63%. The company had revenue of $6.23 million during the quarter, compared to the consensus estimate of $5.85 million. Equities analysts anticipate that Champions Oncology will post 0.17 EPS for the current year.

In related news, Director Daniel Newman Mendelson sold 8,333 shares of the company’s stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $13.02, for a total value of $108,495.66. Following the sale, the director now directly owns 62,500 shares in the company, valued at $813,750. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joel Ackerman sold 22,535 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $17.02, for a total value of $383,545.70. Following the completion of the sale, the director now owns 1,021,731 shares in the company, valued at $17,389,861.62. The disclosure for this sale can be found here. Insiders sold 35,868 shares of company stock worth $560,791 over the last quarter. 44.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in CSBR. EAM Investors LLC bought a new position in shares of Champions Oncology during the 3rd quarter worth approximately $3,144,000. Renaissance Technologies LLC boosted its holdings in shares of Champions Oncology by 164.3% during the 3rd quarter. Renaissance Technologies LLC now owns 265,846 shares of the biotechnology company’s stock worth $4,644,000 after buying an additional 165,246 shares in the last quarter. Ingalls & Snyder LLC bought a new position in shares of Champions Oncology during the 3rd quarter worth approximately $2,772,000. JPMorgan Chase & Co. bought a new position in shares of Champions Oncology during the 3rd quarter worth approximately $2,162,000. Finally, Tocqueville Asset Management L.P. bought a new position in shares of Champions Oncology during the 2nd quarter worth approximately $729,000. Institutional investors and hedge funds own 47.83% of the company’s stock.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Further Reading: Candlestick

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.